Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07137910 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment increased: 60 → 200 participants
    • Trial sites expanded: 1 → 12 locations
    • Trial arms changed: 2 → 3
    • Interventions: AHB-137 (Drug) to AHB-137 (Drug), NA therapy (Drug)
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jan 1, 2026 to Dec 12, 2026
    • Start date changed from estimate of Aug 27, 2025 to Sep 4, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.
Trial Details
NCT Number NCT07137910
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions
(from sponsor)		 Chronic Hepatitis B
Related terms Hepatitis B, Chronic
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov